Karyopharm announces national comprehensive cancer network® adds three xpovio® (selinexor) treatment regimens to its clinical practice guidelines in oncology for multiple myeloma

Newton, mass., dec. 11, 2020 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the national comprehensive cancer network® (nccn) added three different xpovio® (selinexor)...
KPTI Ratings Summary
KPTI Quant Ranking